All recurrent episodes in the antibody group had been in patients who was simply hospitalized throughout their initial episode. The subgroup analysis for hospitalization status was performed post hoc. Inpatients were significantly older and had a considerably higher score on Horn’s index than did outpatients, and there was a development toward more severe infections at enrollment among such sufferers . A post hoc analysis showed that among sufferers with a recurrence, 2 of the 7 sufferers in the antibody group had serious diarrhea through the recurrent episode, as compared with 16 of 25 in the placebo group . Medical center Admission after First Episode The mean length of hospitalization for the initial bout of C.A major concern during maintenance therapy is toxicity that limits long-term use and the ability to receive long term treatment after disease progression or that results in life-threatening disorders. Acute myeloid leukemia or the myelodysplastic syndrome provides been reported in individuals with multiple myeloma who didn’t undergo transplantation and were treated with melphalan.35,36 An observational bias is unlikely to explain these findings due to the rapid development of acute myeloid leukemia and, to a smaller degree, the myelodysplastic syndrome. A recent record by the Swedish Cancer Registry described an elevated incidence of these disorders in individuals with multiple myeloma and monoclonal gammopathy of undetermined significance .37 The finding that severe myeloid leukemia or the myelodysplastic syndrome occurs in untreated sufferers with MGUS shows that these plasma-cell disorders are connected with a hematopoietic stem-cell or microenvironmental defect in addition to an effect of chemotherapy exposure.